Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen
Jazz Pharmaceuticals is teaming up with ImmunoGen on a slate of armed antibodies.
Jazz $JAZZ will pay $175 million — $75 million upfront and $100 million in research support — to claim opt-in rights on a lineup of three antibody-drug conjugates either just in the clinic or planned for human studies. At the top of the list is ImmunoGen’s $IMGN Phase I ADC IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia, and IMGN632, a CD123-targeted ADC for hematological malignancies being teed up for its first Phase I. Another program will be designated for the collaboration later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
